The Food and Drug Administration on Thursday issued an emergency use authorization for what it said is the first device that can detect COVID-19 in breath samples.
The InspectIR COVID-19 Breathalyzer is about the size of a piece of carry-on luggage, the FDA said, and can be used in doctor’s offices, hospitals and mobile testing sites. The test, which can provide results in less than three minutes, must be carried out under the supervision of a licensed health care provider.
Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, called the device “yet another example of the rapid innovation occurring with diagnostic tests for COVID-19.”
The FDA said the device was 91.2% accurate at identifying positive test samples and 99.3% accurate at identifying negative test samples.
“InspectIR expects to be able to produce approximately 100 instruments per week, which can each be used to evaluate approximately 160 samples per day,” the agency said. “At this level of production, testing capacity using the InspectIR COVID-19 Breathalyzer is expected to increase by approximately 64,000 samples per month.”
The death toll in the Turkey Syria earthquake has passed 21,000, Minnesota Rep. Angie Craig was attacked, and shots to stop bird flu. Here is everything you Need2Know for Friday, February 10, 2023.
Hundreds of thousands of school age students went missing from the public school rolls during the height of the COVID-19 pandemic and have not been accounted for since.
The Manhattan District Attorney’s office has asked owners and landlords to commence eviction proceedings on unlicensed shops that have popped up all over the city following cannabis legalization across New York in 2021.
